Compare Stocks

→ Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$27.64 -8.3%	$35.61	$17.52 ▼ $43.81	$744.07M	2.6	455,471 shs	609,090 shs
AVDL Avadel Pharmaceuticals	$17.99 -0.6%	$15.43	$9.50 ▼ $18.85	$1.63B	1.6	1.24 million shs	1.61 million shs
CALA Calithera Biosciences	$0.04 -20.0%	$0.03	$0.01 ▼ $0.50	$195K	-0.17	1,618 shs	5,257 shs
CERC Cerecor	$15.94 +4.6%	$2.60	$1.98 ▼ $4.50	$1.53B	1.44	1.27 million shs	222,087 shs
NWBO Northwest Biotherapeutics	$0.50	$0.54	$0.40 ▼ $1.09	$608.28M	-0.68	1.71 million shs	1.25 million shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-8.26%	-13.19%	-16.57%	-14.35%	-0.86%
AVDL Avadel Pharmaceuticals	-0.55%	+11.39%	+14.08%	+19.61%	+78.65%
CALA Calithera Biosciences	-20.00%	+100.00%	+100.00%	+28.00%	-23.08%
CERC Cerecor	0.00%	+5.84%	+259.01%	+288.78%	+465.25%
NWBO Northwest Biotherapeutics	-0.87%	-5.45%	-3.45%	-14.63%	-9.17%

Top 5 AI Stocks to Buy for 2024 (Ad)

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	1.8036 of 5 stars	3.5	0.0	0.0	0.0	2.5	3.3	0.6
AVDL Avadel Pharmaceuticals	3.077 of 5 stars	4.5	2.0	0.0	0.0	3.1	1.7	0.6
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.00	Buy	$61.33	121.90% Upside
AVDL Avadel Pharmaceuticals	3.00	Buy	$22.57	25.47% Upside
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ARCT, AVDL, CERC, CALA, and NWBO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/9/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/20/2024	ARCT Arcturus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00
3/8/2024	ARCT Arcturus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/5/2024	AVDL Avadel Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
3/5/2024	AVDL Avadel Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$18.00 ➝ $23.00
3/5/2024	AVDL Avadel Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$27.00 ➝ $29.00
3/5/2024	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $25.00
3/5/2024	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $22.00
2/8/2024	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
2/6/2024	AVDL Avadel Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$169.93M	4.38	N/A	N/A	$10.42 per share	2.65
AVDL Avadel Pharmaceuticals	$27.96M	58.28	N/A	N/A	$0.98 per share	18.36
CALA Calithera Biosciences	$9.75M	0.02	N/A	N/A	($0.40) per share	-0.10
CERC Cerecor	$6.70M	228.42	N/A	N/A	$0.22 per share	72.45
NWBO Northwest Biotherapeutics	$1.93M	312.43	N/A	N/A	($0.06) per share	-8.35

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$1.04	N/A	5.42	N/A	-15.65%	-18.22%	-11.95%	5/14/2024 (Estimated)
AVDL Avadel Pharmaceuticals	-$160.28M	-$2.04	N/A	21.67	N/A	N/A	-198.06%	-84.51%	5/2/2024 (Estimated)
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	-$63.50M	-$0.57	N/A	N/A	N/A	-1,194.82%	-261.82%	-133.96%	N/A
NWBO Northwest Biotherapeutics	-$62.60M	-$0.06	N/A	∞	N/A	-3,240.11%	N/A	-207.51%	5/8/2024 (Estimated)

Latest ARCT, AVDL, CERC, CALA, and NWBO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/7/2024	Q4 2023	ARCT Arcturus Therapeutics	-$1.69	-$0.32	+$1.37	-$0.32	$64.14 million	$33.99 million
3/5/2024	Q4 2023	NWBO Northwest Biotherapeutics	N/A	-$0.02	-$0.02	-$0.02	N/A	$0.45 million
3/4/2024	Q4 2023	AVDL Avadel Pharmaceuticals	-$0.28	-$0.32	-$0.04	-$0.29	$17.41 million	$19.45 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
CERC Cerecor	N/A	N/A	N/A	N/A	N/A
NWBO Northwest Biotherapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.72	4.72
AVDL Avadel Pharmaceuticals	N/A	3.64	3.36
CALA Calithera Biosciences	N/A	N/A	N/A
CERC Cerecor	0.79	2.19	2.18
NWBO Northwest Biotherapeutics	N/A	0.09	0.09

Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
AVDL Avadel Pharmaceuticals	69.19%
CALA Calithera Biosciences	N/A
CERC Cerecor	62.84%
NWBO Northwest Biotherapeutics	0.04%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	13.80%
AVDL Avadel Pharmaceuticals	4.00%
CALA Calithera Biosciences	6.60%
CERC Cerecor	45.70%
NWBO Northwest Biotherapeutics	9.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	26.92 million	23.20 million	Optionable
AVDL Avadel Pharmaceuticals	154	90.58 million	86.95 million	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
CERC Cerecor	31	96.01 million	N/A	Not Optionable
NWBO Northwest Biotherapeutics	25	1.20 billion	1.09 billion	Not Optionable

ARCT, AVDL, CERC, CALA, and NWBO Headlines

Source	Headline
	Northwest Biotherapeutics (OTCMKTS:NWBO) Stock Passes Below 200-Day Moving Average of $0.67 americanbankingnews.com - April 16 at 3:34 AM
	Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors prnewswire.com - March 21 at 11:09 AM
	‘Spoofing’ case might draw back curtain on high-speed trading firms ft.com - March 2 at 10:11 AM
	Northwest Biotherapeutics, Inc. (NWBO) uk.finance.yahoo.com - February 29 at 2:53 PM
	Northwest Biotherapeutics Stock (OTC:NWBO), Short Interest Report benzinga.com - February 23 at 12:07 AM
	Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification finance.yahoo.com - February 7 at 4:37 PM
	Northwest Biotherapeutics submits marketing application to UK MHRA for DCVax-L msn.com - December 22 at 10:28 AM
	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax-L For Glioblastoma finanznachrichten.de - December 21 at 12:53 PM
	Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma finance.yahoo.com - December 21 at 12:53 PM
	Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application finance.yahoo.com - November 22 at 2:22 PM
	Northwest Biotherapeutics Inc NWBO morningstar.com - October 31 at 12:12 PM
	Northwest Bio: Another Small Filing Delay msn.com - October 14 at 10:44 AM
	NW Bio dips on announcing delay in submission of marketing application for DCVax seekingalpha.com - October 13 at 12:56 PM
	Northwest Biotherapeutics Shares Slide on Application Delay marketwatch.com - October 13 at 12:56 PM
	Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application finance.yahoo.com - October 13 at 12:56 PM
	Police searching for suspects in Northwest DC shooting wjla.com - October 10 at 10:28 AM
	Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board finance.yahoo.com - September 12 at 6:48 PM
	Sports Betting In The Northwest Territories- Is it Legal? Best Sportsbooks In The NWT basketballinsiders.com - August 30 at 6:42 PM
	Northwest Bio: Is There Ever Going To Be A Right Time? msn.com - August 17 at 9:29 PM
	Northwest Missouri State University usnews.com - August 6 at 5:59 PM
	Northwest Hospital health.usnews.com - August 4 at 6:51 PM
	Standing Stone Circles: The most ancient builders of Northwest Arabia nationalgeographic.com - August 3 at 8:41 AM
	Siloam Springs News nwaonline.com - July 22 at 1:52 PM
	Why Northwest Bio Is Shunned by Savvy Health Care Investors thestreet.com - July 15 at 2:20 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arcturus Therapeutics

NASDAQ:ARCT

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Avadel Pharmaceuticals

NASDAQ:AVDL

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Cerecor

NASDAQ:CERC

Cerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Northwest Biotherapeutics

OTCMKTS:NWBO

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial